Drug Trial Radar · NCT06501651
Sacubitril/Valsartan Treats Patients With Essential Hypertension and Type 2 Diabetic Nephropathy
Last checked: Nov 20, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
297
Planned (sponsor's estimate)
Start
Aug 1, 2024
Primary completion
Apr 10, 2025
Study completion Apr 10, 2025
Sponsor
- Lead sponsor
- Sichuan Academy of Medical SciencesAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- The Second Affiliated Hospital of Chongqing Medical University; Nanchong Central Hospital; The People's Hospital of Leshan; The Affiliated Traditional Chinese Medicine Hospital Of Southwest Medical University; Chengdu First People's Hospital; Mianyang People's Hospital; Guang'an people's hospital of Sichuan province; Meishan Traditional Chinese Medicine Hospital; Qijiang District People's Hospital; Meishan People's Hospital; The First People's Hospital of Guangyuan; Dazhou Central Hospital
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to compare the efficacy and safety of Sacubitril/Valsartan versus Valsartan in patients with essential hypertension and type 2 diabetic nephropathy over a 12-week treatment period, including two treatment groups, with a total of 297 eligible subjects randomly assigned in a 2:1 ratio to either the experimental group or the control group.Subjects will participate in the study through two phases: the screening period and the follow-up period.The primary outcome measure is the change in systolic blood pressure from baseline after 12 weeks of treatment.
Conditions
- Essential Hypertension
- Type 2 Diabetes
- Nephropathy
Interventions
Sacubitril/ValsartanDrug
Sacubitril/Valsartan is a novel antihypertensive medication composed of an angiotensin II receptor blocker (ARB) Valsartan and a neprilysin inhibitor Sacubitril in a 1:1 molar co-crystal form. Sacubitril is a prodrug that, once ingested, is metabolized by esterases into its active form, which inhibits neprilysin activity. Neprilysin has various substrates, including natriuretic peptides and angiotensin II (Ang II). By inhibiting neprilysin, the levels of natriuretic peptides that have antihypertensive and organ-protective effects are increased. The other component, Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing additional antihypertensive and organ-protective effects. The co-crystal structure ensures that Sacubitril and Valsartan have similar absorption and elimination rates, thereby synchronizing their pharmacological effects.
ValsartanDrug
Valsartan, effectively inhibits the Ang II type 1 receptor (AT1R), providing both antihypertensive and organ-protective effects.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction in 24-hour ambulatory systolic blood pressure(SBP)Time frame: From enrollment to the end of treatment at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.